Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -9.97% is 55% above its 5-year average of -22.36%, near the high end of its 5-year range (-34.07%–-9.97%).
51.57% above its 12-month average of -20.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.21%.
RETURN ON ASSETS (ROA)
-9.97%
RETURN ON ASSETS (ROA) AVG TTM
-20.59%
RETURN ON ASSETS (ROA) AVG 3Y
-24.65%
RETURN ON ASSETS (ROA) AVG 5Y
-22.36%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+51.57%
CURRENT VS 3Y AVG
+59.56%
CURRENT VS 5Y AVG
+55.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.88%
median of 431 covered companies
CURRENT VS SECTOR MEDIAN
+58.25%
vs the sector median at left
Adaptive Biotechnologies Corporation
Market Cap
$4.78B
Return on Assets (ROA)
-9.97%
TTM Avg
-20.59%
3Y Avg
-24.65%
5Y Avg
-22.36%
Market Cap
$4.81B
Return on Assets (ROA)
-31.79%
TTM Avg
-38.86%
3Y Avg
-47.00%
5Y Avg
-47.76%
Market Cap
$4.92B
Return on Assets (ROA)
-2.47%
TTM Avg
-26.65%
3Y Avg
-27.96%
5Y Avg
-27.52%
Market Cap
$5.02B
Return on Assets (ROA)
4.59%
TTM Avg
-6.29%
3Y Avg
-18.57%
5Y Avg
-18.57%
Market Cap
$4.50B
Return on Assets (ROA)
-34.36%
TTM Avg
-56.86%
3Y Avg
-55.14%
5Y Avg
-55.14%
Market Cap
$5.11B
Return on Assets (ROA)
-66.02%
TTM Avg
-31.80%
3Y Avg
-35.60%
5Y Avg
-41.38%
Market Cap
$5.20B
Return on Assets (ROA)
-78.04%
TTM Avg
-72.67%
3Y Avg
-59.05%
5Y Avg
-50.29%
Market Cap
$5.20B
Return on Assets (ROA)
5.08%
TTM Avg
4.88%
3Y Avg
4.58%
5Y Avg
3.44%
Market Cap
$4.34B
Return on Assets (ROA)
-41.11%
TTM Avg
-28.92%
3Y Avg
-26.43%
5Y Avg
-22.29%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.78B | -9.97% | -20.59% | -24.65% | -22.36% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | -31.79% | -38.86% | -47.00% | -47.76% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -2.47% | -26.65% | -27.96% | -27.52% |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 4.59% | -6.29% | -18.57% | -18.57% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.50B | -34.36% | -56.86% | -55.14% | -55.14% |
| Erasca, Inc. (ERAS)vs › | $5.11B | -66.02% | -31.80% | -35.60% | -41.38% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | -78.04% | -72.67% | -59.05% | -50.29% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 5.08% | 4.88% | 4.58% | 3.44% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.34B | -41.11% | -28.92% | -26.43% | -22.29% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.27B | -45.20% | -56.55% | -55.28% | -47.01% |
ROA
-10.0%
ROE
-44.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -11.60% |
| 2024-12-31 | -29.57% |
| 2023-12-31 | -34.07% |
| 2022-12-31 | -23.37% |
| 2021-12-31 | -22.45% |
| 2020-12-31 | -13.10% |
| 2019-12-31 | -7.52% |
| 2018-12-31 | -13.96% |
| 2017-12-31 | -11.82% |
